Oppenheimer Holdings, Inc. reissued their buy rating on shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) in a report released on Friday morning. The brokerage currently has a $27.00 price objective on the biotechnology company’s stock. Oppenheimer Holdings also issued estimates for Heron Therapeutics’ FY2020 earnings at $1.45 EPS and FY2021 earnings at $3.29 EPS.

HRTX has been the subject of a number of other research reports. Mizuho reaffirmed a buy rating and issued a $28.00 price target on shares of Heron Therapeutics in a report on Tuesday, November 7th. Cantor Fitzgerald set a $31.00 price target on shares of Heron Therapeutics and gave the company a buy rating in a report on Friday, October 20th. Cowen and Company reaffirmed a buy rating and issued a $40.00 price target on shares of Heron Therapeutics in a report on Monday, November 6th. BidaskClub raised shares of Heron Therapeutics from a sell rating to a hold rating in a report on Saturday, August 26th. Finally, Jefferies Group LLC reaffirmed a buy rating and issued a $26.00 price target on shares of Heron Therapeutics in a report on Friday, July 14th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the stock. Heron Therapeutics currently has an average rating of Buy and a consensus target price of $28.36.

Shares of Heron Therapeutics (NASDAQ HRTX) traded down $0.55 during trading hours on Friday, hitting $15.80. 883,400 shares of the company were exchanged, compared to its average volume of 818,124. The company has a quick ratio of 2.02, a current ratio of 2.12 and a debt-to-equity ratio of 0.62. Heron Therapeutics has a 1 year low of $12.21 and a 1 year high of $20.85.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.77) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.87) by $0.10. Heron Therapeutics had a negative net margin of 831.89% and a negative return on equity of 385.11%. The firm had revenue of $8.57 million during the quarter, compared to the consensus estimate of $8.12 million. sell-side analysts forecast that Heron Therapeutics will post -3.42 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Heron Therapeutics’ (HRTX) “Buy” Rating Reaffirmed at Oppenheimer Holdings, Inc.” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/11/14/heron-therapeutics-hrtx-buy-rating-reaffirmed-at-oppenheimer-holdings-inc.html.

Institutional investors have recently bought and sold shares of the stock. Janus Henderson Group PLC purchased a new stake in Heron Therapeutics in the 2nd quarter worth about $78,134,000. Virtu KCG Holdings LLC raised its position in Heron Therapeutics by 62.5% in the 2nd quarter. Virtu KCG Holdings LLC now owns 25,053 shares of the biotechnology company’s stock worth $347,000 after purchasing an additional 9,637 shares during the period. Bank of New York Mellon Corp raised its position in Heron Therapeutics by 7.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 204,857 shares of the biotechnology company’s stock worth $2,837,000 after purchasing an additional 14,086 shares during the period. Teachers Advisors LLC raised its position in Heron Therapeutics by 20.5% in the 1st quarter. Teachers Advisors LLC now owns 69,720 shares of the biotechnology company’s stock worth $1,046,000 after purchasing an additional 11,862 shares during the period. Finally, Royce & Associates LP purchased a new stake in Heron Therapeutics in the 2nd quarter worth about $796,000.

About Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Stock Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related stocks with our FREE daily email newsletter.